Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Visual pathway glioma
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 47 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029, NCI-2012-03173, CDR667932, PBTC-029B, NCT01089101
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Binimetinib in Treating Younger Patients with Progressive or Recurrent Solid Tumors or Low-Grade Gliomas
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 1 to less than 18
Trial IDs: ChildrensHLA, NCI-2014-02168, NCT02285439
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: CLEE011XUS17T, NCI-2016-01570, NCT02607124
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Modafinil in Treating Children with Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 to 19
Trial IDs: ACCL0922, NCI-2011-02594, CDR0000702733, SCUSF 0901, NCT01381718
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 18
Trial IDs: CHOA2725-14, NCI-2015-00181, IRB00074563, NCT02343224
Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 201604002, NCI-2016-00549, NCT02689336
INFUSE Bone Graft in Treating Patients with Tibial Pseudarthrosis and Neurofibromatosis 1 Undergoing Surgery
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 2 to 18
Trial IDs: F150922005, NCI-2017-00197, NCT02718131
Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621SC, NCI-2017-01251, NCT03155620
Pediatric MATCH: Selumetinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Activating MAPK Pathway Mutations
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621E, NCI-2017-01250, NCT03213691
Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621A, NCI-2017-01264, NCT03213704
Memantine Hydrochloride in Preventing Cognitive Decline in Pediatric Patients with Low Grade Glioma Undergoing Radiation Therapy
Status: Not yet active
Phase: Phase II
Type: Supportive care
Age: 6 to 21
Trial IDs: MEMCRT, NCI-2017-01279, NCT03194906
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Lenalidomide and Radiation Therapy in Treating Children with Pontine Glioma or High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 19 at diagnosis
Trial IDs: 8449, NCI-2011-02539, 100219, CDR0000687467, NCI-10-C-0219, P10687, 10-C-0219, NCT01226940
Ramucirumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1416, NCI-2015-00744, NCT02564198
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: NLG2105, NCI-2015-01872, NCT02502708
Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1513, NCI-2016-00708, NCT02780804
Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 22
Trial IDs: RXDX-101-03, NCI-2016-00924, NCT02650401
Start Over